<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02672423</url>
  </required_header>
  <id_info>
    <org_study_id>16169</org_study_id>
    <secondary_id>I3Y-MC-JPCC</secondary_id>
    <nct_id>NCT02672423</nct_id>
  </id_info>
  <brief_title>A Study of Abemaciclib in Healthy Participants</brief_title>
  <official_title>A Bioequivalence Study Comparing Abemaciclib Capsule and Tablet Formulations and Effect of Food on Abemaciclib Tablet Pharmacokinetics in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure how much abemaciclib gets into the blood stream and
      how long it takes the body to get rid of it when given as capsules versus a tablet(s). The
      effect of a high fat meal on the tablet formulation will also be evaluated. In addition, the
      tolerability of abemaciclib tablet and capsule formulations will be evaluated. Information
      about any side effects that may occur will also be collected.

      This study has 3 parts. Parts A and C will last about 44 days including follow-up. Part B
      will last about 60 days including follow-up. Screening may occur up to 28 days before the
      first dose of study drug. Participants are only allowed to enroll in one part.

      This study is for research purposes only and is not intended to treat any medical condition.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration versus Time Curve from Zero to Infinity (AUC[0-∞])</measure>
    <time_frame>Predose through day 9 postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax)</measure>
    <time_frame>Predose through day 9 postdose</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Abemaciclib Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of abemaciclib tablet (test formulation) or abemaciclib capsules (reference formulation) on Day 1 in each of 2 periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abemaciclib Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of abemaciclib tablet(s) (test formulation) or abemaciclib capsules (reference formulation) on Day 1 in each of 3 periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abemaciclib Fasted/Fed Part C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of abemaciclib tablet (test formulation) with or without a meal on Day 1 in each of 2 periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib Capsules (Reference Formulation)</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Abemaciclib Part A</arm_group_label>
    <arm_group_label>Abemaciclib Part B</arm_group_label>
    <other_name>LY2835219</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib Tablet(s) (Test Formulation)</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Abemaciclib Part A</arm_group_label>
    <arm_group_label>Abemaciclib Part B</arm_group_label>
    <arm_group_label>Abemaciclib Fasted/Fed Part C</arm_group_label>
    <other_name>LY2835219</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy surgically sterile or postmenopausal females and sterile males

          -  Have a body mass index (BMI) 18 to 32 kilograms per square meter (kg/m²)

        Exclusion Criteria:

          -  Have known allergies to abemaciclib, related compounds, or any components of the
             formulation

          -  Regularly use known drugs of abuse and/or show positive findings on urinary drug
             screening

          -  Show evidence of human immunodeficiency virus (HIV) infection and/or positive human
             HIV antibodies

          -  Show evidence of hepatitis C and/or positive hepatitis C antibody

          -  Show evidence of hepatitis B and/or positive hepatitis B surface antigen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Daytona Beach Clinical Research Unit</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evansville Clinical Research Unit</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2016</study_first_submitted>
  <study_first_submitted_qc>February 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2016</study_first_posted>
  <last_update_submitted>November 3, 2016</last_update_submitted>
  <last_update_submitted_qc>November 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <pending_results>
    <submitted>October 27, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

